Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients WithFSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Learn More
Posters

Sparsentan Publications 2023

Learn More
Posters HCU

Population-based Incidence Estimates of Classical Homocystinuria Using the Genome Aggregation Database (gnomAD)

Learn More
Posters HCU

A Longitudinal Study of Cognitive Function in Classical Homocystinuria (HCU) Demonstrates Distinct Deficits in Inhibitory Control

Learn More
Posters HCU

Insights from the First Genetic Evaluation of a Longitudinal Natural History Study in Classical Homocystinuria (HCU)

Learn More
Posters HCU

Population-based Incidence Estimates of Classical Homocystinuria Using the Genome Aggregation Database (gnomAD)

Learn More
Posters HCU

A Longitudinal Study of Cognitive Function in Classical Homocystinuria (HCU) Demonstrates Distinct Deficits in Inhibitory Control

Learn More
Posters HCU

Insights from the First Genetic Evaluation of a Longitudinal Natural History Study in Classical Homocystinuria (HCU)

Learn More
Posters HCU

Pegtibatinase, an Investigational Enzyme Replacement Therapy for the Treatment of Classical Homocystinuria: Initial Results From the Phase 1/2 COMPOSE Study

Learn More
Posters HCU

Pegtibatinase, an Investigational Enzyme Replacement Therapy for the Treatment of Classical Homocystinuria: Initial Results from the Phase 1/2 COMPOSE Study

Learn More
Posters HCU

Dietary Goals and Current Challenges in the Management of Classical Homocystinuria: Insights From Multinational Real-World Experience

Learn More
Posters

Sparsentan, the dual endothelin and angiotensin receptor antagonist (DEARA), improves kidney function and lifespan and protects against hearing loss in Alport mice with developed renal structural changes

Learn More
Posters

Sparsentan for Treatment of Pediatric Patients With Selected Proteinuric Glomerular Diseases: Design of thePhase 2 EPPIK Study

Learn More